An open index of research

A status.lu publication

Medicine

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

Françoise Barré-Sinoussi, Jean-Claude Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, Luc Montagnier

Published 20 May 1983 · Science · Journal article

Summary

The authors reported the isolation of a novel retrovirus from a lymph-node biopsy of a patient with lymphadenopathy considered at risk for AIDS. The virus exhibited magnesium-dependent reverse transcriptase activity, budded as a type-C particle, and showed tropism for T lymphocytes, but was antigenically and biologically distinct from the known human T-cell leukemia viruses (HTLV-I/II). This agent—later designated lymphadenopathy-associated virus (LAV) and subsequently recognized as HIV—was proposed as a candidate cause of AIDS.

Key findings

  • A new T-lymphotropic retrovirus with characteristic reverse-transcriptase activity was isolated from a patient with persistent lymphadenopathy at risk for AIDS.
  • The isolate was distinct from previously described human retroviruses (HTLV-I/II) in its antigenic and biological properties.
  • The findings implicated this novel retrovirus as a possible etiologic agent of AIDS, laying the groundwork for identifying HIV.

Subjects & keywords

Cite this paper

APA

Françoise Barré-Sinoussi, Jean-Claude Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, & Luc Montagnier (1983). Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS). Science. https://doi.org/10.1126/science.6189183

BibTeX
@article{barrsinoussi1983isolation,
  author    = {Françoise Barré-Sinoussi and Jean-Claude Chermann and F. Rey and M. T. Nugeyre and S. Chamaret and Luc Montagnier},
  title     = {Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)},
  journal   = {Science},
  year      = {1983},
  doi       = {10.1126/science.6189183},
  url       = {https://doi.org/10.1126/science.6189183}
}

Related in Medicine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, et al.

This multinational, randomized, placebo-controlled phase 2/3 trial evaluated the safety and efficacy of two 30-µg doses of the BNT162b2 lipid-nanoparticle mRNA vaccine, given 21 days apart, in 43,548 participants 16 years of age or older. Among those without prior SARS-CoV-2 infection, the vaccine conferred 95% protection against laboratory-confirmed Covid-19 beginning at least 7 days after the second dose. The safety profile over a median of about two months was characterized by short-lived, mostly mild-to-moderate reactions, with a low incidence of serious adverse events comparable to placebo.

New England Journal of Medicine Open access

Smoking and Carcinoma of the Lung; Preliminary Report

Richard Doll and A. Bradford Hill

In this hospital-based case-control study, Doll and Hill interviewed roughly 700 patients with carcinoma of the lung and a comparison group of patients with other diseases across London hospitals to assess the association between tobacco smoking and lung cancer. They found that lung-cancer patients were substantially more likely to be smokers and to be heavy smokers than the controls, with risk rising with the amount smoked. The authors concluded that smoking is an important factor in the production of carcinoma of the lung.

British Medical Journal Open access

On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ

Alexander Fleming

Fleming reported that a mould of the genus Penicillium, which had contaminated a culture plate, produced a diffusible substance—which he named 'penicillin'—that inhibited the growth of many common pathogenic bacteria. He characterized the antibacterial spectrum and potency of the crude culture filtrate, showing it was strongly active against Gram-positive organisms (such as staphylococci and streptococci) while sparing certain Gram-negative bacilli. He proposed using the agent both as a selective culture medium for isolating Bacillus influenzae and as a relatively non-toxic antiseptic.

British Journal of Experimental Pathology Open access